doi: 10.1007/BF00194597.
Phase II study of 4'-deoxydoxorubicin in advanced colorectal cancer
- PMID: 3733376
- DOI: 10.1007/BF00194597
Item in Clipboard
Phase II study of 4'-deoxydoxorubicin in advanced colorectal cancer
Invest New Drugs.
1986.
Abstract
Thirty-three patients with advanced colorectal cancer were entered on a phase II study of 4'-deoxydoxorubicin (esorubicin) (30-35 mg/m2 q 3 weekly). Objective response was documented in 4 of 25 previously untreated patients and in none of 8 previously treated patients. Toxicity was acceptable with grade 3 or 4 leukopenia occurring in 8 patients. Complete alopecia occurred only in 4 patients and gastro-intestinal toxicity was mild. A significant decrease (greater than 10%) of the left ventricular ejection fraction occurred in 8/23 patients who received greater than 2 courses of treatment.
Similar articles
-
Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.Invest New Drugs. 1989 Nov;7(4):333-6. doi: 10.1007/BF00173763. Invest New Drugs. 1989. PMID: 2557300
-
Phase II evaluation of 4'-epi-doxorubicin in patients with advanced colorectal carcinoma.Cancer Treat Rep. 1982 Sep;66(9):1757-8. Cancer Treat Rep. 1982. PMID: 6956441
-
Phase II trial of esorubicin in patients with advanced colorectal carcinoma.Cancer Treat Rep. 1986 Oct;70(10):1241-2. Cancer Treat Rep. 1986. PMID: 3530453 Clinical Trial. No abstract available.
-
Phase II study of esorubicin in patients with advanced colorectal carcinoma and no prior chemotherapy: an Illinois Cancer Council Trial.Cancer Treat Rep. 1987 Jul-Aug;71(7-8):765-6. Cancer Treat Rep. 1987. PMID: 3300969 Clinical Trial. No abstract available.
-
Phase II trial of esorubicin (4' deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma.Invest New Drugs. 1986;4(3):269-74. doi: 10.1007/BF00179595. Invest New Drugs. 1986. PMID: 3818231
Cited by
-
Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma. Results of an Eastern Cooperative Oncology Group study (EST 2685).Invest New Drugs. 1990 Aug;8(3):329-32. doi: 10.1007/BF00171849. Invest New Drugs. 1990. PMID: 2272773 Clinical Trial.
-
Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.Invest New Drugs. 1990 May;8(2):221-6. doi: 10.1007/BF00177265. Invest New Drugs. 1990. PMID: 2166722
-
Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature.Cancer Chemother Pharmacol. 1988;21(4):347-50. doi: 10.1007/BF00264203. Cancer Chemother Pharmacol. 1988. PMID: 3286024 Review.